



US006649345B2

(12) **United States Patent**
Richardson

(10) **Patent No.:** **US 6,649,345 B2**
(45) **Date of Patent:** **Nov. 18, 2003**

(54) **PHENYLALANINE HYDROXYLASE GENE VARIANTS, AND AMINO ACID AND PTERIN HOMEOSTASIS, IN THE DEFINITION, DETECTION, TREATMENT AND PREVENTION OF PSYCHOTIC, MOOD AND PERSONALITY DISORDERS**

(75) Inventor: **Mary Ann Richardson**, New York, NY (US)

(73) Assignee: **New York State Office of Mental Health**, Albany, NY (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 170 days.

(21) Appl. No.: **09/734,188**

(22) Filed: **Dec. 12, 2000**

(65) **Prior Publication Data**

US 2002/0106645 A1 Aug. 8, 2002

Related U.S. Application Data

(62) Division of application No. 09/253,025, filed on Feb. 19, 1999, now Pat. No. 6,200,758.

(51) **Int. Cl.⁷** **C12Q 1/68**; C07H 19/00; C07H 19/048; C07H 5/06

(52) **U.S. Cl.** **435/6**; 435/810; 536/27; 536/28; 536/29; 935/77; 935/78

(58) **Field of Search** 435/6, 810; 536/27, 536/28, 29; 935/77, 78

(56) **References Cited**

U.S. PATENT DOCUMENTS

4,965,190 A	10/1990	Woo et al.	
5,393,784 A	2/1995	Richardson	
5,670,539 A	9/1997	Richardson	
5,919,823 A	7/1999	Richardson	
6,025,193 A	2/2000	Weiss	
6,026,322 A *	2/2000	Korenman	600/547
6,034,091 A	3/2000	Dante	
6,117,890 A *	9/2000	Bymaster	514/342

OTHER PUBLICATIONS

Abola EE et al., "Protein data bank archives of three-dimensional macromolecular structures" *Methods Enzymol* 1997; 277:556-571.

Aebischer P et al., "Long-term cross-species brain transplantation of a polymer-encapsulated dopamine-secreting cell line" *Experimental Neurology* 1991; 111: 269-275.

Andreou ER and Prokipcak D, "Analysis of human CYP7A1 mRNA decay in Hep-G2 cells by reverse transcription-polymerase chain reaction" *Arch Biochem Biophys* 1998; 357: 137-146.

Berry HK et al., "Reduction of cerebrospinal fluid phenylalanine after oral administration of Valine, Isoleucine, and Leucine" *Pediatr Res* 1982; 16: 751-755.

Berry HK et al., "Preliminary support for the oral administration of Valine, Isoleucine and Leucine for phenylketonuria" *Dev Med Child Neurol* 1985; 27: 33-39.

Berry HK et al., "Valine, Isoleucine, and Leucine" *Amer J of Diseases of Children* 1990; 144: 539-543.

Bjerkenstedt L et al., "Plasma amino acids in relation to cerebrospinal fluid monoamine metabolites in schizophrenic patients and healthy controls" *Br J Psychiatry* 1985; 147: 276-282.

Bjorgo E et al., "Partial characterization and three-dimensional-structural localization of eight mutations in exon 7 of the human phenylalanine hydroxylase gene associated with phenylketonuria" *Eur J Biochem* 1998; 257: 1-10.

Blumenthal MD, "Mental illness in parents of phenylketonuric children" *J Psychiatr Res* 1967; 5: 59-74.

Boulton AA et al., "Phenylethylamine in the CNS: effects of monoamine oxidase inhibiting drugs, deuterium substitution and lesions and its role in the neuromodulation of catecholaminergic neurotransmission" *J Neural Transmission Suppl* 1990; 29: 119-129.

Burcin MM et al., "Adenovirus-mediated regulable target gene expression in vivo" *Proc Nat Acad Sci USA* 1999; 96: 355-360.

Caballero B and Wurtman RJ, "Control of Plasma phenylalanine levels" Ch. 1, In: Wurtman RJ and Ritter-Walker E, eds. *Dietary Phenylalanine and Brain Function*. Boston: Birkhauser, 1988; 9-23.

Cloninger CR et al., "Genome-wide search for schizophrenia susceptibility loci: The NIMH genetics initiative and millennium consortium" *Am J Med Genet* 1998; 81: 275-281.

Cole SP et al., "Human monoclonal antibodies" *Mol Cell Biochem* 1984; 62: 109-120.

Daniel PM et al., "Amino acid precursors of monoamine neurotransmitters and some factors influencing their supply to the brain" *Psychol Med* 1976; 6: 277-286.

Dawson E et al., "Genetic association between alleles of pancreatic phospholipase A2 gene and bipolar affective disorder" *Psychiatric Genetics* 1995; 5: 177-180.

Desviat LR et al., "Molecular basis of non-PKU hyperphenylalaninaemia in Spain: Prevalence of A403V, a mutation with high residual activity" *J Inher Metab Dis* 1996; 19: 227-230.

(List continued on next page.)

Primary Examiner—Gary Benzion
Assistant Examiner—Arun Kr. Chakrabarti
(74) *Attorney, Agent, or Firm*—Sughrue Mion, PLLC

(57) **ABSTRACT**

The present invention describes sequence variants in the phenylalanine hydroxylase gene, and biochemical measures of amino acid and pterin homeostasis, which are associated with Psychotic, Mood and Personality Disorders. Methods for the definition of etiological/pathophysiological subtypes of the disorders and for the detection of disorder susceptibility are provided. Treatment and prophylactic strategies targeted at the elaborated psychopathology are also disclosed.

4 Claims, No Drawings